Celnova and Vectans Pharma announced they have signed an exclusive licensing agreement whereby Celnova will have the rights to commercialize in Argentina the once daily local buccal tablet of Miconazole Lauriad® for the treatment of oral thrush, Loramyc® 50mg.

« This partnership is an important milestone in our development plan and reinforces our international strategy . Next step, the Loramyc®’s MA submission. » said Jérôme Théron, CEO Vectans Pharma.